Scholar Rock Jumps 320% On Final-Phase Win In Spinal Muscular Atrophy
In this article:
Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study.